UBS initiated coverage of Harmony Biosciences with a Buy rating and $56 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences management to meet with Needham
- Harmony Biosciences reports Q2 EPS 20c, consensus (6c)
- Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
- Needham healthcare analysts hold analyst/industry conference call
- Harmony Biosciences management to meet virtually with Piper Sandler